European Pentoxifylline Multi-Infarct Dementia Study

Autor: Rong-Chi Chen, Yoshio Suzuki, Florence Pasquier, P. Siira, Jan G.E. Weerts, Tetsuya Iidaka, Hiroshi Maruoka, Peter Rieckmann, K. Yagi, Didier Leys, Thierry Kuntzer, Christian Kremser, K. Kushida, Gerhard Luef, Yukiko Fujimatsu, J. Zeitlhofer, P. Baumann, Frederik Barkhof, François Mounier-Vehier, Hans-Christoph Diener, V. C. Monetti, Philip Scheltens, Jan De Bleecker, Hirohumi Fukuda, G. Heger, Liesbeth van Aken, Gerhard Bauer, V.V. Myllylä, Juhani Sivenius, Rosario Pascarella, Ulrich A. Walker, Kotaro Oizumi, Franz Aichner, Tadayuki Maehara, E. Sindern, Yoshiaki Honda, Maria Rosaria Tola, Andreas Bitsch, G. Birbamer, S. Passero, Ming-Jang Chiu, Edward Byrne, H. Vanharanta, Danielle David, Kazuyuki Kawamoto, Ilaria Casetta, Andreas Thiel, Brigitte H. Bendixen, T. Ohishi, Luc Cinotti, C. Romano, Henry J.M. Barnett, G. Tribl, M. Mondelli, Guy van den Abeele, Chiu-yu Tseng, Annik Charnallet, M. Takahashi, Hiroyasu Shiraishi, H. Thoma, T. Inoue, Maria Luisa Caniatti, Johannes Burtscher, K. Kawana, F. Mosler, Jens D. Rollnik, Torn Nakajima, P. Della Porta, Harold P. Adams, Heather E. Meldrum, William van Landegem, K. Howorka, Pellat J, B. im Spring, P. Anderer, J.P. Malin, Enrico Granieri, Hilmar Prange, Takeshi Asoh, Steven J. Collins, Yoshihiro Sato, Claude Cuvelier, A. Rossi, Stephan Felber, Olivier Moreaud
Rok vydání: 1996
Předmět:
Zdroj: European Neurology. 36:315-321
ISSN: 1421-9913
0014-3022
DOI: 10.1159/000117279
Popis: A double-blind, placebo-controlled, parallel-group, multicentre study was conducted to evaluate the efficacy of pentoxifylline (Trental) in patients with multi-infarct dementia (MID) according to DSM-III-R criteria. Men and women aged 45 years or older, with a Hachinski Ischemia Scale scoreor = 7 and a Mini Mental State Examination (MMSE) score of 10-25 at entry, and computed tomographic evidence of vascular disease were enrolled. A total of 289 patients were randomised to receive either oral pentoxifylline 400 mg t.i.d. or placebo for 9 months, and efficacy was assessed every 3 months. The primary outcome variable was the difference in scores between the two treatment groups, as measured on the Gottfries, Bråne, Steen (GBS) scale. Secondary outcome variables included the scores achieved on the Sandoz Clinical Assessment Geriatric (SCAG) scale and MMSE, and a battery of psychological and other tests. The intention-to-treat analysis for patients completing the study (n = 239) showed a statistically significant difference in the total GBS score in favour of pentoxifylline (improvement of 3.5 points, p = 0.028). A significant difference in the total GBS score in favour of pentoxifylline was even almost achieved in the intention-to-treat analysis for all evaluable patients (n = 269, improvement of 2.1 points, p = 0.065). It is concluded that treatment with pentoxifylline is beneficial for patients with MID, the global results of the GBS and SCAG scales being reinforced by significant improvements in those subscales specific for intellectual and cognitive function.
Databáze: OpenAIRE